GlobeNewsWire
25 Sept 2026, 13:45 UTC · 1h ago
Verdict
Headline leans bearish. We score DVLT −1.00 across two claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
2 claims · scored −1 bearish … +1 bullish · 1 new · 1 priced in
ARS Pharmaceuticals reported on June 24, 2026, that no new commercial formulary additions or coverage decisions for neffy were issued in the July 1, 2026 cycle.
Priced inevent occurred June 24, 2026
So whatThe resulting 23.9% price drop to $8.02 suggests the market has already discounted the lack of immediate payer access for the product.
More negative than 90% of claims this week
Continue reading
5 related stories
More negative than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Kaplan Fox & Kilsheimer LLP announced on September 25, 2026, a securities class action lawsuit against ARS Pharmaceuticals Inc. regarding losses suffered between March 9 and June 24, 2026.
Newpress release dated Sept. 25, 2026
So whatLegal expenses and potential settlements typically impact net income in subsequent quarters, though the lead plaintiff deadline is October 5, 2026.
More negative than 70% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is the subject of a newly announced securities class action lawsuit.
More negative than 95% of ticker scores this week
The company is the subject of a newly announced securities class action lawsuit.
More negative than 95% of ticker scores this week
The company is facing a securities class action lawsuit following a significant stock price drop due to poor payer access updates for its product neffy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
5h ago
+0.9%
Price is moving against the score
$0.1528 vs $0.1515 close before publication (Sep 24) · not market-adjusted
DVLT chart →
